Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) Return on Equity (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Return on Equity for 6 consecutive years, with 0.67% as the latest value for Q3 2025.

  • Quarterly Return on Equity rose 812.0% to 0.67% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 0.67% through Sep 2025, up 812.0% year-over-year, with the annual reading at 0.54% for FY2024, 71.0% up from the prior year.
  • Return on Equity for Q3 2025 was 0.67% at Inhibikase Therapeutics, down from 0.53% in the prior quarter.
  • The five-year high for Return on Equity was 0.24% in Q3 2021, with the low at 8.79% in Q3 2024.
  • Average Return on Equity over 5 years is 1.31%, with a median of 0.67% recorded in 2025.
  • The sharpest move saw Return on Equity tumbled -763bps in 2024, then surged 812bps in 2025.
  • Over 5 years, Return on Equity stood at 0.36% in 2021, then crashed by -116bps to 0.78% in 2022, then crashed by -97bps to 1.55% in 2023, then surged by 61bps to 0.61% in 2024, then fell by -10bps to 0.67% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 0.67%, 0.53%, and 0.43% for Q3 2025, Q2 2025, and Q1 2025 respectively.